Assessment of the Efficacy and Pulmonary Toxicity of Trastuzumab Deruxtecan in HER2-Positive and HER2-Low Metastatic Breast Cancer in a Tertiary Center in the United Arab Emirates

Our real-world experience confirms that the efficacy of T-DXd in UAE is consistent with published data from published phase 3 clinical trials. The incidence of clinical pulmonary toxicity is much lower than anticipated, and until further data is available, it may be reasonable to continue using the 12-weekly assessment scans to monitor patients for interstitial lung disease (ILD). Further studies are needed to determine the optimal imaging frequency for monitoring ILD.